Modulating innate antiviral immunity and, in particular, the pDC/type I IFN axis since the early phases of COVID-19 may help to pinpoint novel pharmacological strategies or host-directed therapies that would counter-act the raising of hyper-inflammation and the resulting diffuse damage contributing to a rapid resolution of SARS-CoV-2 infection. The gene discussed is PDC; the disease is COVID-19.